Rosendahl Amalie, Uth Louise Margrethe Kiær, Weis Nina, Smerup Morten, Ellesøe Sabrina Gade
Department of Anaesthesiology, Herlev and Gentofte Hospital, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Clin Med Insights Pediatr. 2025 Jan 28;19:11795565251315722. doi: 10.1177/11795565251315722. eCollection 2025.
Pediatric patients undergoing cardiac surgery prior to 1992 in Denmark were at risk of hepatitis C virus (HCV) infection through donor blood used in extracorporeal circulation. HCV screening became possible in donors in 1991, eliminating the risk of iatrogenic infections. No formalized screening has been conducted for patients receiving non-screened blood, potentially leaving some with undetected HCV infection.
This study aimed to determine the prevalence of chronic HCV infection in this group of patients and offer treatment to those affected.
Nationwide cross-sectional study.
Between 2020 and 2023, 1645 individuals who underwent pediatric heart surgery before 1992 in Denmark were identified. Participants were invited for HCV screening using anti-HCV-antibody and HCV-RNA tests. Patients testing positive for HCV were referred to direct-acting antiviral (DAA) treatment.
Of 1645 patients identified, 571 consented to participate, and 246 completed HCV screening. Two individuals tested positive for chronic HCV infection, resulting in a prevalence of 0.8%. Both patients were asymptomatic for many years before treatment and successfully cleared the virus after DAA treatment.
The 0.8% prevalence of HCV in this cohort is higher than in the general Danish population although lower than in similar studies from the U.S. and Germany. This may reflect Denmark's practice of unpaid blood donation, reducing infection risks. Targeted screening for at-risk cohorts exposed to transfusions before 1992 could aid in HCV detection and treatment, potentially preventing long-term liver complications.
The study was approved by the Capital Region Ethics Board in Denmark (j.nr. H-18062088).
1992年以前在丹麦接受心脏手术的儿科患者有通过体外循环中使用的供血感染丙型肝炎病毒(HCV)的风险。1991年开始能够对供血者进行HCV筛查,消除了医源性感染风险。对于接受未筛查血液的患者尚未进行正规筛查,这可能使一些患者的HCV感染未被发现。
本研究旨在确定该组患者中慢性HCV感染的患病率,并为受影响者提供治疗。
全国性横断面研究。
在2020年至2023年期间,确定了1645名1992年以前在丹麦接受小儿心脏手术的个体。邀请参与者使用抗HCV抗体和HCV-RNA检测进行HCV筛查。HCV检测呈阳性的患者被转诊接受直接抗病毒药物(DAA)治疗。
在确定的1645名患者中,571名同意参与,246名完成了HCV筛查。两名个体慢性HCV感染检测呈阳性,患病率为0.8%。两名患者在治疗前多年均无症状,在接受DAA治疗后成功清除病毒。
该队列中HCV的患病率为0.8%,高于丹麦普通人群,但低于美国和德国的类似研究。这可能反映了丹麦无偿献血的做法,降低了感染风险。对1992年以前有输血暴露风险的队列进行针对性筛查有助于HCV的检测和治疗,有可能预防长期肝脏并发症。
该研究获得了丹麦首都地区伦理委员会的批准(编号H-18062088)。